TrueMark Investments LLC Sells 3,054 Shares of Schrödinger, Inc. (NASDAQ:SDGR)

TrueMark Investments LLC lessened its holdings in Schrödinger, Inc. (NASDAQ:SDGR) by 7.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 36,946 shares of the company’s stock after selling 3,054 shares during the period. TrueMark Investments LLC’s holdings in Schrödinger were worth $713,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Avanza Fonder AB bought a new stake in shares of Schrödinger during the 4th quarter valued at approximately $577,000. Barclays PLC grew its stake in shares of Schrödinger by 421.6% during the third quarter. Barclays PLC now owns 107,554 shares of the company’s stock worth $1,995,000 after buying an additional 86,933 shares during the last quarter. State Street Corp increased its holdings in shares of Schrödinger by 1.8% during the third quarter. State Street Corp now owns 2,155,620 shares of the company’s stock worth $39,987,000 after buying an additional 38,972 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Schrödinger by 60.2% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,510,518 shares of the company’s stock valued at $67,718,000 after acquiring an additional 1,319,464 shares during the last quarter. Finally, Rubric Capital Management LP boosted its holdings in shares of Schrödinger by 17.7% during the 3rd quarter. Rubric Capital Management LP now owns 3,685,503 shares of the company’s stock valued at $68,366,000 after acquiring an additional 555,503 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity

In other news, CFO Geoffrey Craig Porges sold 5,491 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $21.76, for a total value of $119,484.16. Following the transaction, the chief financial officer now directly owns 27,544 shares of the company’s stock, valued at $599,357.44. The trade was a 16.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 8.60% of the company’s stock.

Schrödinger Trading Down 5.7 %

NASDAQ SDGR opened at $21.45 on Wednesday. The firm has a market capitalization of $1.57 billion, a PE ratio of -9.17 and a beta of 1.62. The business’s 50-day moving average price is $23.03 and its two-hundred day moving average price is $20.79. Schrödinger, Inc. has a 12 month low of $16.67 and a 12 month high of $29.15.

Schrödinger (NASDAQ:SDGR) last announced its earnings results on Wednesday, February 26th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.20). The company had revenue of $88.32 million during the quarter, compared to the consensus estimate of $83.20 million. Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. As a group, analysts forecast that Schrödinger, Inc. will post -2.37 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on SDGR. Piper Sandler lowered their target price on Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. KeyCorp upped their price objective on Schrödinger from $25.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Schrödinger presently has a consensus rating of “Buy” and an average price target of $32.29.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.